RecruitingPhase 2NCT05837806
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Studying Upper tract urothelial carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tianjin Medical University Second Hospital
- Principal Investigator
- Hailong Hu, MD,PhDTianjin Medical University Second Hospital
- Intervention
- tislelizumab+disitamab-vedotin(drug)
- Enrollment
- 21 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (1)
- The Second Hospital of Tianjin Medical University, Tianjin, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05837806 on ClinicalTrials.govOther trials for Upper tract urothelial carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07321210Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical TrialTianjin Medical University Second Hospital
- RECRUITINGNCT07452432Korean Prospective Upper Tract Urothelial Carcinoma CohortSamsung Medical Center
- RECRUITINGPHASE2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc
- RECRUITINGPHASE2NCT07225374Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCSamsung Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07492225Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized TrialChanghai Hospital
- RECRUITINGPHASE2NCT06356155Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial CancerUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT07126119Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCTianjin Medical University Second Hospital
- RECRUITINGPHASE1NCT06848868Ambulatory Flexible URS for UTUC SurveillanceChinese University of Hong Kong